CLINICAL_TRIALS
trial_result
· 2014-05-22
Clinical Trial Update: Safety and Pharmacokinetics of TT30 in Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH) [Phase 1]
Summary
A Phase 1 study evaluated the safety and pharmacokinetics of TT30 in patients with paroxysmal nocturnal hemoglobinuria. The trial was terminated.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: Paroxysmal Nocturnal Hemoglobinuria (PNH) | Phase 1 | Status: TERMINATED